Literature DB >> 22536778

Nicotinic acid hydroxamate downregulated the melanin synthesis and tyrosinase activity through activating the MEK/ERK and AKT/GSK3β signaling pathways.

Yin-Shiou Lin1, Mao-Te Chuang, Chao-Hsiang Chen, Mei-Yin Chien, Wen-Chi Hou.   

Abstract

In this study, nicotinic acid hydroxamate (NAH), a nicotinic acid derivative, was found to show dose-dependent inhibition of melanin content and tyrosinase activity of murine melanoma B16F10 cells with or without being cotreated with cAMP stimulators. In the studies on signaling pathways for skin whitening, NAH-treated B16F10 cells resulted in a decrease in the expression of tyrosinase, tyrosinase-related protein-1, and microphthalmia-associated transcription factor (MITF). PD98059 and LY294002 additions were obviously to increase melanin contents in B16F10 cells; however, they were reversed by NAH cotreatments. NAH-mediated increases in the phosphorylation of mitogen-activated protein kinase kinase (MEK)/ERK and AKT/glycogen synthase kinase-3β (GSK3β) were also found, which in turn led to the inhibition of MITF expression and then downregulated tyrosinase and tyrosinase-related protein (TRP)-1 expressions. These results suggest that NAH may be an active component in the inhibition of melanogenesis, which will have potential uses as cosmetics for whitening and need further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22536778     DOI: 10.1021/jf301109p

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  8 in total

1.  Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study.

Authors:  Sang-Woon Lee; Seong-Gon Kim; Young-Wook Park; Haeyong Kweon; Jwa-Young Kim; Horatiu Rotaru
Journal:  Tumour Biol       Date:  2013-02-15

2.  Bioprocess development for nicotinic acid hydroxamate synthesis by acyltransferase activity of Bacillus smithii strain IITR6b2.

Authors:  Shilpi Agarwal; Meenu Gupta; Bijan Choudhury
Journal:  J Ind Microbiol Biotechnol       Date:  2013-06-23       Impact factor: 3.346

3.  Down-regulation of tyrosinase, TRP-1, TRP-2 and MITF expressions by citrus press-cakes in murine B16 F10 melanoma.

Authors:  Sang Suk Kim; Min-Jin Kim; Young Hun Choi; Byung Kok Kim; Kwang Sik Kim; Kyung Jin Park; Suk Man Park; Nam Ho Lee; Chang-Gu Hyun
Journal:  Asian Pac J Trop Biomed       Date:  2013-08

4.  Soyasaponin Ag inhibits α‑MSH‑induced melanogenesis in B16F10 melanoma cells via the downregulation of TRP‑2.

Authors:  Seung Hwan Yang; Aristides M Tsatsakis; George Tzanakakis; Hong-Suk Kim; Bao Le; Maria Sifaki; Demetrios A Spandidos; Chigen Tsukamoto; Kirill S Golokhvast; Boris N Izotov; Gyuhwa Chung
Journal:  Int J Mol Med       Date:  2017-07-10       Impact factor: 4.101

5.  Neobavaisoflavone Inhibits Melanogenesis through the Regulation of Akt/GSK-3β and MEK/ERK Pathways in B16F10 Cells and a Reconstructed Human 3D Skin Model.

Authors:  Da Eun Kim; Bo Yoon Chang; Sang Ok Ham; Youn Chul Kim; Sung Yeon Kim
Journal:  Molecules       Date:  2020-06-09       Impact factor: 4.411

6.  Azastilbene analogs as tyrosinase inhibitors: new molecules with depigmenting potential.

Authors:  Larissa Lavorato Lima; Rebeca Mól Lima; Annelisa Farah da Silva; Antônio Márcio Resende do Carmo; Adilson David da Silva; Nádia Rezende Barbosa Raposo
Journal:  ScientificWorldJournal       Date:  2013-02-12

7.  Melanogenesis Inhibitor(s) from Phyla nodiflora Extract.

Authors:  Feng-Lin Yen; Moo-Chin Wang; Chan-Jung Liang; Horng-Huey Ko; Chiang-Wen Lee
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-12       Impact factor: 2.629

8.  Antioxidant Compounds, Kirenol and Methyl ent-16α, 17-dihydroxy-kauran-19-oate Bioactivity-Guided Isolated from Siegesbeckia glabrescens Attenuates MITF-Mediated Melanogenesis via Inhibition of Intracellular ROS Production.

Authors:  Sun-Yup Shim; Ye Eun Lee; Mina Lee
Journal:  Molecules       Date:  2021-03-30       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.